These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36484525)

  • 1. Clinical and immunological effects of hydroxychloroquine in patients with active rheumatoid arthritis despite antirheumatic treatment.
    Takei H; Takanashi S; Otomo K; Hanaoka H; Kikuchi J; Yamaoka K; Yoshimoto K; Abe T; Takeuchi T; Kaneko Y
    Mod Rheumatol; 2023 Dec; 34(1):50-59. PubMed ID: 36484525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.
    Hua L; Du H; Ying M; Wu H; Fan J; Shi X
    Medicine (Baltimore); 2020 Jul; 99(27):e20824. PubMed ID: 32629668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.
    Zeng X; Zhao D; Radominski SC; Keiserman M; Lee CK; Meerwein S; Enejosa J; Sui Y; Mohamed MF; Park W
    Int J Rheum Dis; 2021 Dec; 24(12):1530-1539. PubMed ID: 34779576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review.
    Rempenault C; Combe B; Barnetche T; Gaujoux-Viala C; Lukas C; Morel J; Hua C
    Arthritis Care Res (Hoboken); 2020 Jan; 72(1):36-40. PubMed ID: 30629341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis.
    Faselis C; Zeng-Treitler Q; Cheng Y; Kerr GS; Nashel DJ; Liappis AP; Weintrob AC; Karasik PE; Arundel C; Boehm D; Heimall MS; Connell LB; Taub DD; Shao Y; Redd DF; Sheriff HM; Zhang S; Fletcher RD; Fonarow GC; Moore HJ; Ahmed A
    Arthritis Rheumatol; 2021 Sep; 73(9):1589-1600. PubMed ID: 33973403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
    Munster T; Gibbs JP; Shen D; Baethge BA; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; Lindsley H; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D; Furst DE
    Arthritis Rheum; 2002 Jun; 46(6):1460-9. PubMed ID: 12115175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.
    Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D;
    Ann Rheum Dis; 2013 Sep; 72(9):1488-95. PubMed ID: 22984173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
    Genovese MC; Greenwald M; Codding C; Zubrzycka-Sienkiewicz A; Kivitz AJ; Wang A; Shay K; Wang X; Garg JP; Cardiel MH
    Arthritis Rheumatol; 2017 May; 69(5):932-942. PubMed ID: 28118538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.
    Furst DE; Lindsley H; Baethge B; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D
    Arthritis Rheum; 1999 Feb; 42(2):357-65. PubMed ID: 10025931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis.
    Cordova Sanchez A; Khokhar F; Olonoff DA; Carhart RL
    Cardiovasc Drugs Ther; 2024 Apr; 38(2):297-304. PubMed ID: 36197529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
    Zhao J; Zhou W; Wu Y; Ji P; Yang L; Yan X; Zhang Z
    BMC Med Inform Decis Mak; 2021 Mar; 21(1):83. PubMed ID: 33663487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.
    Lillegraven S; Paulshus Sundlisæter N; Aga AB; Sexton J; Olsen IC; Fremstad H; Spada C; Madland TM; Høili CA; Bakland G; Lexberg Å; Hansen IJW; Hansen IM; Haukeland H; Ljoså MA; Moholt E; Uhlig T; Solomon DH; van der Heijde D; Kvien TK; Haavardsholm EA
    JAMA; 2021 May; 325(17):1755-1764. PubMed ID: 33944875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.